Lorazepam 2mg IM Can Cause Decreased Oxygen Saturation
Yes, Ativan (lorazepam) 2mg IM can cause decreased oxygen saturation, particularly when combined with other sedatives or opioids, in elderly patients, or in those with underlying respiratory disease. The FDA label explicitly lists respiratory depression and apnea as adverse reactions to lorazepam 1, and clinical guidelines emphasize that benzodiazepines predispose patients to hypoxemia 2.
Evidence from Drug Labeling
The FDA-approved labeling for Ativan states that adverse reactions include "respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease" 1. Importantly, the label notes that "most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent" 1. However, the label also indicates that "in single high doses Ativan has a tranquilizing action on the central nervous system with no appreciable effect on the respiratory or cardiovascular systems" in healthy volunteers 1.
Clinical Evidence of Oxygen Desaturation
Multiple studies demonstrate oxygen desaturation with lorazepam:
In cardiac surgery patients, lorazepam 3-4mg caused significantly lower minimum oxygen saturation values compared to no sedation, though total time below 90% was similar 3
In geriatric patients under spinal anesthesia, oral lorazepam 1mg caused hypoxemia (SpO2 <90%) in 20% of patients, compared to 15% in unpremedicated controls 4. The study found that 74% of drowsy patients with high spinal levels experienced desaturation versus only 7% of awake patients with lower levels 4
In premedicated cardiac surgery patients, a combination of lorazepam, morphine, and droperidol caused progressive oxygen desaturation in all patients, with 12 of 15 developing hypoxemia or severe hypoxemia requiring immediate oxygen administration 5
High-Risk Populations and Situations
Age >55 years is the most consistent predictor of desaturation during sedation 2. Additional risk factors include:
- Combination with opioids: Benzodiazepines and opioids have a potentiating effect in suppressing respirations 2
- Drowsiness/deep sedation: Significantly increases desaturation risk 4
- Underlying cardiopulmonary disease 2
Clinical Management Algorithm
Monitoring requirements per ASA guidelines 6:
- Continuous pulse oximetry is mandatory - it reliably detects early oxygen desaturation 2
- Maintain IV access throughout the procedure and until no longer at risk for cardiorespiratory depression 6
- Titrate to effect - ensure previous dose has taken full effect before administering additional drug 6
- Reduce doses when combining sedatives and analgesics due to respiratory depression risk 6
Oxygen administration: All episodes of desaturation in the studies were easily corrected with supplemental oxygen 4. However, oxygen administration during sedation may delay detection of hypoventilation 2.
Critical Timing
Most serious adverse events occur within 25 minutes of the last IV dose, with a median time of approximately 2 minutes after final medication administration 2. For IM lorazepam specifically, peak plasma levels occur at approximately 2 hours following administration 1, though absorption from IM injection is rapid with peak levels at 1.15 hours and absorption half-life of 14.2 minutes 7.
Common Pitfall
Do not rely solely on pulse oximetry - it should not substitute for clinical assessment of level of consciousness and respiratory effort 2. Pulse oximetry cannot detect early hypoventilation and hypercarbia that may precede apnea 2.